| Stereochemistry | ACHIRAL |
| Molecular Formula | I |
| Molecular Weight | 122.905597944 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | -1 |
SHOW SMILES / InChI
SMILES
[123I-]
InChI
InChIKey=XMBWDFGMSWQBCA-AHCXROLUSA-M
InChI=1S/HI/h1H/p-1/i1-4
| Molecular Formula | HI |
| Molecular Weight | 123.91354 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Iodide ion I-123 is the most suitable isotope of iodine for the diagnostic study of thyroid diseases. Sodium Iodide I 131 Capsules Diagnostic is indicated for use in adults for: Assessment of thyroid function using radioactive iodine (RAI) uptake test and Imaging the thyroid (scintigraphy). The following adverse reaction has been described elsewhere in the labeling: Hypersensitivity Reactions. The following adverse reactions have been identified during post-approval use from Sodium Iodide I 131 Capsules Diagnostic: Gastrointestinal disorders (vomiting, nausea, and diarrhea); General disorders and administration site conditions (local thyroid swelling); Immune system disorders (hypersensitivity reactions); Skin and subcutaneous tissue disorders (itching, rash, hives, and erythema). Certain drugs and iodine-containing foods interfere with the accumulation of radioiodide by the thyroid.
Approval Year
Sample Use Guides
The recommended oral dose range for diagnostic studies of thyroid function in the average adult patient (70 kg) is 3.7-14.8 MBq (100-400 uCi) of Sodium Iodide I-123. The lower portion of the range 3.7 MBq (100 uCi) is recommended for uptake studies alone, and the higher portion 14.8 MBq (400 uCi) for thyroid imaging.
Route of Administration:
Oral
